Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
180
datasets available to search
ShareScore release 0.9.0
Dataset results
180 results for “corticosteroid treatment”
The Upper-Airway Microbiome as a Biomarker of Asthma Exacerbations despite Inhaled Corticosteroid Treatment
<p>The response to inhaled corticosteroids (ICS) in asthma is affected by the interplay of several factors. Among these, the role of the upper-airway microbiome has been scarcely investigated. We aimed to evaluate the association between the salivary, pharyngeal, and nasal microbiome with asthma exacerbations despite ICS use. Samples from 250 asthma patients from the Genomics and Metagenomics of Asthma Severity (GEMAS) study treated with ICS were analyzed. Controls/cases were defined by the absence/presence of asthma exacerbations in the past six months despite being treated with ICS. The bacterial microbiota was profiled by sequencing the V3-V4 region of the 16S rRNA gene. Differences between groups were assessed by PERMANOVA and regression models adjusted for potential confounders. A false discovery rate (FDR) of 5% was used to correct for multiple comparisons. Classification models of asthma exacerbations despite ICS treatment were built with machine learning approaches based on clinical, genetic, and microbiome data. In nasal and saliva samples, cases had lower bacterial diversity (Richness, Shannon, and Faith indexes) than controls (0.007≤p≤0.037). Asthma exacerbations accounted for 8-9% of the interindividual variation of the salivary and nasal microbiomes (0.003≤p≤0.046). Three, four, and eleven bacterial genera from the salivary, pharyngeal, and nasal microbiomes were differentially abundant between groups (4.09x10<sup>-12</sup>≤FDR≤0.047). Integrating clinical, genetic, and microbiome data showed good discrimination for the development of asthma exacerbations despite ICS use (AUC<sub>training</sub>:0.82 and AUC<sub>validation</sub>:0.77). The diversity and composition of the upper-airway microbiome are associated with asthma exacerbations despite ICS treatment. The salivary microbiome has a potential application as a biomarker of asthma exacerbations despite ICS use.</p> <p>The summary results of the association between bacterial genera and asthma exacerbations despite ICS use are published in this repository. Analyses were conducted using the DESeq2 package adjusting for potential confounders (see more details in the manuscript). The submitted summary tables contains the following columns:</p> <ul> <li>Kingdom: Taxonomic classification at Kingdom level</li> <li>Phylum: Taxonomic classification at Phylum level</li> <li>Class: Taxonomic classification at Class level</li> <li>Order: Taxonomic classification at Order level</li> <li>Family: Taxonomic classification at Family level</li> <li>Genus: Taxonomic classification at Genus level</li> <li>log2FC: log<sub>2</sub>(fold-change). Positive values indicate higher abundance in cases and negative values in controls</li> <li>SE: standard error of log<sub>2</sub>(fold-change)</li> <li>P.Value: p-value of the regression model</li> <li>FDR: adjusted p-value by false discovery rate (Benjamin-Hochberg method)</li> </ul>
Human Genetics Influences Microbiome Composition Involved in Asthma Exacerbations despite Inhaled Corticosteroid Treatment
<p>Additional Supplement Data of the manuscript Perez-Garcia J, Espuela-Ortiz A, Hernández-Pérez JM, et al. Human Genetics Influences Microbiome Composition Involved in Asthma Exacerbations despite Inhaled Corticosteroid Treatment (in press). <em>J Allergy Clin Immunol</em>. 2023;S0091-6749(23)00748-0. doi:10.1016/j.jaci.2023.05.021.</p> <p>This Supplement Data contains the following items:</p> <table> <tbody> <tr> <td>Additional Table 1</td> <td>List of independent mbQTLs associated with p<1x10<sup>-5</sup> in the mbGWAS from saliva samples in Europeans (discovery).</td> </tr> <tr> <td>Additional Table 2</td> <td>List of independent mbQTLs associated with p<1x10<sup>-5</sup> in the mbGWAS from pharyngeal samples in Europeans (discovery).</td> </tr> <tr> <td>Additional Table 3</td> <td>List of independent mbQTLs associated with p<1x10<sup>-5</sup> in the mbGWAS from nasal samples in Europeans (discovery).</td> </tr> <tr> <td>Additional Table 4</td> <td>Summary results of enrichment analyses using the Enrichr platform.</td> </tr> <tr> <td>Additional Table 5</td> <td>Summary results of stratified enrichment analyses by biological sample type.</td> </tr> <tr> <td>Additional Table 6</td> <td>List of independent mbQTLs associated with p<1x10<sup>-5</sup> in the mbGWAS from saliva samples in African Americans (replication phase).</td> </tr> <tr> <td>Additional Table 7</td> <td>List of independent mbQTLs associated with p<1x10<sup>-5</sup> in the mbGWAS from saliva samples in Latinos (replication phase).</td> </tr> <tr> <td>Additional Table 8</td> <td>Summary results of replication enrichment analyses in saliva samples.</td> </tr> <tr> <td>Additional Table 9</td> <td>Summary statistics of the mbQTL analysis of <em>Streptococcus</em> in nasal samples.</td> </tr> <tr> <td>Additional Table 10</td> <td>Summary statistics of the mbQTL analysis of <em>Campylobacter</em> in pharyngeal samples.</td> </tr> <tr> <td>Additional Table 11</td> <td>Summary statistics of the mbQTL analysis of <em>Tannerella</em> in pharyngeal samples.</td> </tr> <tr> <td>Additional Table 12</td> <td>Summary table of the different genetic models tested for each mbQTL pair.</td> </tr> </tbody> </table>
Risk of bias assessments and support for judgement with ROB 2 tool for the Cochrane Review-Update: Systemic corticosteroids for the treatment of COVID-19.
<p>Risk of bias assessments and support for judgement with ROB 2 tool for the Cochrane Review-Update: Systemic corticosteroids for the treatment of COVID-19.</p>
A Randomized Control Trial to Evaluate the Efficacy of Autologous Blood Injection Versus Local Corticosteroid Injection for Treatment of Lateral Epicondylitis
ClinicalTrials.gov study NCT00947765. IPD Sharing: Not stated. Countries: 1. Publications: 1.
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
ClinicalTrials.gov study NCT03139604. IPD Sharing: NO. Countries: 19. Publications: 2.
Early Treatment of Acute Graft Versus Host Disease With Bone Marrow-Derived Mesenchymal Stem Cells and Corticosteroids
ClinicalTrials.gov study NCT02379442. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With CJA Treated by Corticosteroid Therapy
ClinicalTrials.gov study NCT00174291. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Corticosteroids With Placebo Versus Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH)
ClinicalTrials.gov study NCT01074437. IPD Sharing: Not stated. Countries: 1. Publications: 2.
A Prospective Trial of Cooled Radiofrequency Ablation of Medial Branch Nerves Versus Facet Joint Injection of Corticosteroid for the Treatment of Lumbar Facet Syndrome
ClinicalTrials.gov study NCT03614793. IPD Sharing: YES. Countries: 1. Publications: 1.
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
ClinicalTrials.gov study NCT01537133. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age
ClinicalTrials.gov study NCT01156792. IPD Sharing: YES. Countries: 1. Publications: 1.
Treatment of Preschool Children With Upper Respiratory Tract Illnesses Using Azythromycin and Lower Respiratory Tract Symptoms Using Oral Corticosteroids.
ClinicalTrials.gov study NCT01272635. IPD Sharing: Not stated. Countries: 1. Publications: 2.
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room
ClinicalTrials.gov study NCT01524198. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)
ClinicalTrials.gov study NCT02953678. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Short-term responses to high-dose inhaled corticosteroid treatment in patients with chronic obstructive pulmonary disease having a fractional nitric oxide concentration over 35 parts per billion: a single-center pre-post study
<p>Background: There is currently no strategy to identify chronic obstructive pulmonary disease (COPD) patients whose pulmonary function could benefit from inhaled corticosteroids. This study investigates whether a 28-day regime of inhaled corticosteroids improves pulmonary function test results among chronic obstructive pulmonary disease patients having a fractional exhaled nitric oxide concentration > 35 parts per billion.<br> Methods: This was a single-center one-arm pre–post trial. Chronic obstructive pulmonary disease patients with a fractional exhaled nitric oxide concentration > 35 parts per billion treated at our institution from September 2018 to August 2019 were included. Each patient was administered budesonide (200 μg, 8 puffs daily) for 28 days. The primary outcome measure was the difference between the values of forced expiratory volume in 1 s (FEV1) at baseline and 28 days after inhaled corticosteroid initiation. Secondary outcomes included differences of Chronic Obstructive Pulmonary Disease Assessment Test scores, %FEV1, and that between the percent forced vital capacity at baseline and 28 days after inhaled corticosteroid initiation.<br> Results: Twenty patients were included; all patients completed the 28-day inhaled corticosteroid regime. The mean difference in FEV1 between day 1 and 28 days after inhaled corticosteroid initiation was 340 mL (95% confidence interval: −100 to 770 mL; p = 0.122). The mean differences in secondary outcomes were: % forced vital capacity , −0.16% (95% confidence interval: −2.84 to 2.53%; p = 0.905); %FEV1, 1.63% (95% confidence interval: −4.56 to 7.81%; p = 0.589); Chronic Obstructive Pulmonary Disease Assessment Test score, −2.50 (95% confidence interval: −5.72 to 0.72; p = 0.121).<br> Conclusion: The 28-day course of inhaled corticosteroids showed no significant difference in FEV1 for chronic obstructive pulmonary disease patients having fractional exhaled nitric oxide concentration > 35 parts per billion.<br> </p>
Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment in Quiescent Systemic Lupus
ClinicalTrials.gov study NCT02558517. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy
ClinicalTrials.gov study NCT00367562. IPD Sharing: Not stated. Countries: 1. Publications: 10.
Treatment Efficacy of Systemic Corticosteroids in AECOPD Patients With Higher Blood Eosinophil Levels
ClinicalTrials.gov study NCT05059873. IPD Sharing: YES. Countries: 1. Publications: 9.
Corticosteroid Treatment for Community-Acquired Pneumonia - The STEP Trial
ClinicalTrials.gov study NCT00973154. IPD Sharing: Not stated. Countries: 1. Publications: 10.
ADjunctive coRticosteroid trEatment iN criticAlly ilL Patients With Septic Shock
ClinicalTrials.gov study NCT01448109. IPD Sharing: Not stated. Countries: 5. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.